|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.785 USD | +4.10% |
|
+0.41% | -7.43% |
| 07-16 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 06-01 | Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Bullish |
| Resistance | 10.26 | 11.62 | 11.62 |
| Spread/Res. | -5.26% | -16.35% | -16.35% |
| Spread/Supp. | +9.58% | +13.42% | +28.06% |
| Support | 8.87 | 8.57 | 7.59 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- IMTX Stock
- Charts Immatics N.V.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
